• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of an orally disintegrating films containing polaprezinc for prevention of oral mucositis in pediatric patients with cancer

Research Project

Project/Area Number 20K07152
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionGifu University

Principal Investigator

Suzuki Akio  岐阜大学, 医学部附属病院, 准教授 (80775148)

Co-Investigator(Kenkyū-buntansha) 林 秀樹  岐阜薬科大学, 薬学部, 教授 (00419665)
田原 耕平  岐阜薬科大学, 薬学部, 教授 (30454325)
小林 亮  岐阜大学, 大学院医学系研究科, 非常勤講師 (50555662)
Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords口内炎 / ポラプレジンク / 粘膜付着性フィルム / 抗がん剤 / 携帯型近赤外分光装置 / 粘膜付着フィルム / 小児 / 化学療法
Outline of Research at the Start

本研究でははじめに口腔粘膜付着性フィルム製剤の処方を決定する。ここでは、フィルム剤の最適な粘着性(服用感、溶解性)を決め、さらに、甘味料や香料により小児が服用しやすい味(甘味)に調整する。
次に作製した製剤を日本薬局方に準じて含量均一試験および安定性試験(6か月まで検討)を実施する。
最後に、岐阜大学医学部附属病院小児科において、がん化学療法が施行される小児患者を対象に口内炎の発現率および重症度(CTCAE version 4.0に基づき評価)を検討する。症例数は2年間で20例を予定している。なお、本研究は特定臨床研究に該当するため、審査可能な施設に申請を行い承認後に実施する。

Outline of Final Research Achievements

Oral mucositis is one of the most debilitating complications of cancer treatment. We previously reported that oral ingestion of polaprezinc suspended in sodium alginate solution prevents oral mucositis in patients receiving high-dose chemotherapy for hematopoietic stem cell transplantation. The aim of this study is to develop the oral mucoadhesive film containing polaprezinc for children. We prepared the oral mucoadhesive film containing polaprezinc and revealed the characterization of formulation by each pharmaceutical tests. Moreover, we indicated that near-infrared spectroscopy was able to predict the polaprezinc concentration in the present oral mucoadhesive film. We are preparing clinical research to evaluate the usefulness of the present oral mucoadhesive film.

Academic Significance and Societal Importance of the Research Achievements

本研究では、小児へ適応可能なPZ含有粘膜付着性フィルム製剤の製剤特性を明らかにし、臨床研究へと展開可能な製剤を開発した。PZの口内炎に対する有効性は、非盲検化ランダム化比較試験において成人患者に対し示されている。さらに、小児患者では後方視的な研究においてその有効性が示されていたが、服用感に問題があった。現在、Paliferminが唯一米国FDAにて造血幹細胞移植前の大量抗がん剤投与に伴う口内炎に適応を有しているが、小児患者への安全性は明らかになっていない。本研究結果は、がん治療に伴う小児の口内炎に対する有用な予防・治療薬の開発に繋がり、がん治療におけるQOLの向上に大きく貢献できると考える。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (14 results)

All 2023 2022 2021 2020

All Journal Article (8 results) (of which Int'l Joint Research: 6 results,  Peer Reviewed: 8 results,  Open Access: 5 results) Presentation (5 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients with Thoracic Cancer Receiving Platinum-based Chemotherapy2023

    • Author(s)
      Kinomura M, Iihara H, Fujii H, Hirose C, Endo J, Yanase K, Inui T, Kaito D, Sasaki Y, Gomyo T, Sakai-Masuda C, Kawae D, Kitamura Y, Fukui M, Kobayashi R, Ohno Y and Suzuki A
    • Journal Title

      Anticancer Resarch

      Volume: 43 Issue: 3 Pages: 1301-1307

    • DOI

      10.21873/anticanres.16277

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer2022

    • Author(s)
      Fujii H, Sadaka S, Ajisawa K, Okumura N, Makiyama A, Iihara H, Yasufuku I, Ohata K, Kobayashi R, Tanaka Y, Hayashi H, Suzuki A
    • Journal Title

      Anticancer Resarch

      Volume: 42 Issue: 9 Pages: 4581-4588

    • DOI

      10.21873/anticanres.15961

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer2022

    • Author(s)
      Sadaka S, Iwashita T, Fujii H, Kato-Hayashi H, Ohata K, Uemura S, Shimizu M, Suzuki A
    • Journal Title

      Journal of Clinical Medicine

      Volume: 11 Issue: 19 Pages: 5895-5895

    • DOI

      10.3390/jcm11195895

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy.2022

    • Author(s)
      Fujii H, Ueda Y, Hirose C, Ohata K, Sekiya K, Kitahora M, Sadaka S, Yamamoto S, Watanabe D, Kato-Hayashi H, Iihara H, Kobayashi R, Kaburaki M, Matsuhashi N, Takahashi T, Makiyama A, Yoshida K, Suzuki A.
    • Journal Title

      Journal of Pharmaceutical Health Care and Sciences

      Volume: 8 Issue: 1 Pages: 8-8

    • DOI

      10.1186/s40780-022-00239-w

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Comparison of chemotherapy-induced nausea and vomiting between gemcitabine plus nab-paclitaxel combination chemotherapy and gemcitabine monotherapy in patients with advanced pancreatic cancer.2021

    • Author(s)
      Ohata K, Fujii H, Sadaka S, Kato-Hayashi H, Iihara H, Kobayashi R, Uemura S, Iwashita T, Shimizu M, Suzuki A.
    • Journal Title

      Anticancer Research

      Volume: 41 Issue: 7 Pages: 3643-3648

    • DOI

      10.21873/anticanres.15154

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy: a retrospective observational study2021

    • Author(s)
      Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Hayashi H, Sugiyama T, Shimizu M, Suzuki A.
    • Journal Title

      Journal of Pharmaceutical Health Care and Sciences

      Volume: 7 Issue: 1 Pages: 27-27

    • DOI

      10.1186/s40780-021-00210-1

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi‐institutional randomized controlled trial2020

    • Author(s)
      Kitagawa Junichi、Kobayashi Ryo、Nagata Yasuyuki、Kasahara Senji、Ono Takaaki、Sawada Michio、Ohata Koichi、Kato‐Hayashi Hiroko、Hayashi Hideki、Shimizu Masahito、Itoh Yoshinori、Tsurumi Hisashi、Suzuki Akio
    • Journal Title

      International Journal of Cancer

      Volume: 148 Issue: 6 Pages: 1462-1469

    • DOI

      10.1002/ijc.33316

    • NAID

      120007165668

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy2020

    • Author(s)
      Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H, Ohata K, Kumiko Sekiya K, Kitahora M, Matsuhashi N, Takahashi T, Okuda K, Naruse M, Ishihara T, Sugiyama T, Yoshida K, Suzuki A
    • Journal Title

      Supportive Care in Cancer

      Volume: - Issue: 12 Pages: 5943-5952

    • DOI

      10.1007/s00520-020-05443-8

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 口内炎予防を目的としたポラプレジンク含有口腔内粘膜付着フィルム製剤の開発2023

    • Author(s)
      山添 絵理子, 伊藤 拓哉, 伊藤 貴章, 船渡 三結, 鈴木 昭夫, 田原 耕平
    • Organizer
      日本薬学会 第143年会
    • Related Report
      2022 Annual Research Report
  • [Presentation] 胃癌患者における1次治療オキサリプラチンの末梢神経障害が2次治療タキサン系抗がん剤の有効性および安全性に与える影響2022

    • Author(s)
      左髙史織, 藤井宏典, 味澤香苗, 奥村直樹, 牧山明資, 飯原大稔, 安福至, 大畑紘一, 小林亮, 田中善宏, 林秀樹, 鈴木昭夫
    • Organizer
      第32回日本医療薬学会年会
    • Related Report
      2022 Annual Research Report
  • [Presentation] 小児患者における造血幹細胞移植前化学療法に伴う口内炎に対するポラプレジンクの予防効果2022

    • Author(s)
      船渡三結、小関道夫、伊藤拓哉、石原正志、小林亮、大西秀典、田原耕平、鈴木昭夫
    • Organizer
      第50回日本小児神経外科学会
    • Related Report
      2022 Annual Research Report
  • [Presentation] 外来がん化学療法における支持療法への薬学的介入による患者QOLの網羅的定量評価2021

    • Author(s)
      上田祐稀乃,藤井宏典,廣瀬智恵美,大畑紘一,飯原大稔,鏑木美帆,松橋延壽,高橋孝夫,吉田和弘,鈴木昭夫,林秀樹
    • Organizer
      第31回日本医療薬学会年会
    • Related Report
      2021 Research-status Report
  • [Presentation] テモゾロミド併用放射線療法における5-HT3受容体拮抗薬の連日内服の忍容性に関する検討2021

    • Author(s)
      關谷久美子,原田紗希,後藤咲香,藤井宏典,飯原大稔,小林亮,鈴木昭夫
    • Organizer
      第31回日本医療薬学会年会
    • Related Report
      2021 Research-status Report
  • [Patent(Industrial Property Rights)] 口腔用フィルム製剤2022

    • Inventor(s)
      田原耕平、伊藤拓哉、鈴木昭夫
    • Industrial Property Rights Holder
      田原耕平、伊藤拓哉、鈴木昭夫
    • Industrial Property Rights Type
      特許
    • Filing Date
      2022
    • Related Report
      2022 Annual Research Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi